Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

77 more hepatitis cases may trace to clinic
77 more hepatitis cases may trace to clinic Last Update: 1:41 pm (IDM) LAS VEGAS (AP) - Health officials in Las Vegas say 77 more people who were treated at an outpatient clinic have been diagnosed with hepatitis C. Authorities can't say for sure how

Officials: 77 More Hepatitis Cases May Trace To Clinic
LAS VEGAS - Health officials in Las Vegas say 77 more people who were treated at an outpatient clinic have been diagnosed with hepatitis C. Authorities can't say for sure how the 77 people were infected. Officials say they know each was treated from

77 more hepatitis cases may trace to clinic, officials say
LAS VEGAS (AP) ? Seventy-seven more people that were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said. Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior


UPDATES AND COMMENTARY RSS Feed

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...

Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....

Hepatitis E

Food and Drug Administration
Foodborne Pathogenic Microorganisms and Natural Toxins 1992

Name of the Organism: Hepatitis E Virus

Hepatitis E Virus (HEV) has a particle diameter of 32-34 nm, a   buoyant density of 1.29 g/ml in KTar/Gly gradient, and is very  labile. Serologically related smaller (27-30 nm) particles are often found in feces of patients with Hepatitis E and are presumed to represent degraded viral particles. HEV has a single-stranded polyadenylated RNA genome of approximately 8 kb. Based on its physicochemical properties it is presumed to be a calici-like virus.

Name of Acute Disease:

The disease caused by HEV is called hepatitis E, or enterically transmitted non-A non-B hepatitis (ET-NANBH). Other names include fecal-oral non-A non-B hepatitis,and A-like non-A non-B hepatitis.

Note: This disease should not be confused with hepatitis C, also called parenterally transmitted non-A non-B hepatitis (PT-NANBH), or B-like non-A non-B hepatitis, which is a common cause of hepatitis in the U.S.

Nature of Disease:

Hepatitis caused by HEV is clinically indistinguishable from hepatitis A disease. Symptoms include malaise, anorexia, abdominal pain, arthralgia, and fever. The infective dose is not known.

Diagnosis of Human Illness:

Diagnosis of HEV is based on the epidemiological characteristics of the outbreak and by exclusion of hepatitis A and B viruses by serological tests. Confirmation requires identification of the 27-34 nm virus-like particles by immune electron microscopy in feces of acutely ill patients.

Associated Foods:

HEV is transmitted by the fecal-oral route. Waterborne and person-to-person spread have been documented. The potential exists for foodborne transmission.

Frequency of Disease:

Hepatitis E occurs in both epidemic and sporadic-endemic forms, usually associated with contaminated drinking water. Major waterborne epidemics have occurred in Asia and North and East Africa. To date no U.S. outbreaks have been reported.

Usual Course of Disease and Some Complications:

The incubation period for hepatitis E varies from 2 to 9 weeks. The disease usually is mild and resolves in 2 weeks, leaving no sequelae. The fatality rate is 0.1-1% except in pregnant women. This group is reported to have a fatality rate approaching 20%.

Target Populations:

The disease is most often seen in young to middle aged adults (15-40 years old). Pregnant women appear to be exceptionally susceptible to severe disease, and excessive mortality has been reported in this group.

Analysis of Foods:

HEV has not been isolated from foods. No method is currently available for routine analysis of foods.

History of Recent Outbreaks:

Major waterborne epidemics have occurred in India (1955 and1975-1976), USSR (1955-1956), Nepal (1973), Burma (1976-1977), Algeria (1980-1981), Ivory Coast (1983-1984), in refugee camps in Eastern Suddan and Somalia (1985-6), and most recently in Borneo (1987). The first outbreaks reported in the American continents occurred in Mexico in late 1986. To date, no outbreak has occurred in the U.S., but imported cases were identified in Los Angeles in 1987. There is no evidence for immunity against this agent in the American population. Thus, unless other factors (such as poor sanitation or prevalence of other enteric pathogens) are important, the potential for spread to the U.S. is great. Good sanitation and personal hygiene are the best preventive measures.

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 09 May 2008